Company profile: MyMD Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceuticals, including MYMD-1, an oral TNF-alpha inhibitor to regulate the immune system, reduce chronic inflammation, and potentially treat autoimmune and age-related conditions; and Supera-CBD, a synthetic cannabidiol analog targeting CB2 receptors for anxiety, chronic pain, seizures, and potentially addiction.
Products and services
- Clinical-Stage Drug Development: Engineers and advances MYMD-1 and Supera-CBD programs, emphasizing immune regulation, chronic inflammation reduction, and CB2-mediated management of anxiety, pain, seizures, and addiction in clinical-stage development
- MYMD-1: An orally available TNF-alpha inhibitor that regulates immune signaling, reduces chronic inflammation, and potentially treats autoimmune diseases and age-related conditions in a clinical-stage program
- Supera-CBD: A synthetic cannabidiol analog targeting CB2 receptors, developed to manage anxiety, chronic pain, seizures, and potentially addiction with higher potency and bioavailability than plant-derived CBD in a CB2-focused design
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MyMD Pharmaceuticals
Pandion Therapeutics
HQ: United States
Website
- Description: Provider of bispecific antibody therapeutics, modular proteins, and antibodies for localized immunomodulation at the site of disease, enabling durable, tissue-specific treatment for patients with autoimmune and inflammatory diseases and organ transplants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pandion Therapeutics company profile →
Viela Bio
HQ: United States
Website
- Description: Provider of clinical-stage treatments for severe inflammation and autoimmune diseases, with a portfolio that selectively targets shared critical pathways at the root cause of disease; led by global leaders in inflammation and autoimmunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viela Bio company profile →
Genespire
HQ: Italy
Website
- Description: Provider of transformative gene therapies for genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Offers Immune Shielded Lentiviral Vectors for direct liver use enabling long-term hepatocyte-specific expression for one-time treatments, and an Advanced Gene Editing Platform enabling high-efficacy, permanent targeted gene integration in T-cells and HSPCs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genespire company profile →
Alvine Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for autoimmune and gastrointestinal diseases; developing and commercializing treatments including ALV003, a combination protease engineered to digest gluten for patients with celiac disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alvine Pharmaceuticals company profile →
Upstream Bio
HQ: United States
Website
- Description: Provider of antibody therapies targeting the TSLP receptor, developing verekitug (UPB-101), a monoclonal antibody in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and conducting research on Thymic Stromal Lymphopoietin (TSLP) as a driver of inflammatory responses in allergic and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Upstream Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MyMD Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MyMD Pharmaceuticals
2.2 - Growth funds investing in similar companies to MyMD Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MyMD Pharmaceuticals
4.2 - Public trading comparable groups for MyMD Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →